AstraZeneca PLC Director Declaration

Date : 10/03/2019 @ 3:00PM
Source : UK Regulatory (RNS & others)
Stock : Astrazeneca Plc (AZN)
Quote : 7258.0  29.0 (0.40%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca PLC Director Declaration

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Astrazeneca Charts.

TIDMAZN

RNS Number : 7241O

AstraZeneca PLC

03 October 2019

3 October 2019 16:00 BST

Director Declaration

AstraZeneca PLC (the Company) today announced, pursuant to Listing Rule 9.6.14 R (2), that Pascal Soriot, Chief Executive Officer of the Company, is a director of Viela Bio, Inc. which recently completed an initial public offering and listed on the Nasdaq Global Market.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Relations 
 Gonzalo Viña                                                                 +44 203 749 5916 
 Rob Skelding                           Oncology                                   +44 203 749 5821 
 Rebecca Einhorn                        Oncology                                    +1 301 518 4122 
 Matt Kent                              BioPharmaceuticals                         +44 203 749 5906 
 Jennifer Hursit                        Other                                      +44 203 749 5762 
 Christina Malmberg Hägerstrand    Sweden                                     +46 8 552 53 106 
 Michele Meixell                        US                                          +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                               +44 203 749 5712 
 Henry Wheeler                          Oncology                                   +44 203 749 5797 
 Christer Gruvris                       BioPharmaceuticals (CV, metabolism)        +44 203 749 5711 
 Nick Stone                             BioPharmaceuticals (respiratory, renal)    +44 203 749 5716 
 Josie Afolabi                          Other medicines                            +44 203 749 5631 
 Craig Marks                            Finance, fixed income                      +44 7881 615 764 
 Jennifer Kretzmann                     Corporate access, retail investors         +44 203 749 5824 
 US toll-free                                                                      +1 866 381 72 77 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RDNZXLFBKBFZFBQ

(END) Dow Jones Newswires

October 03, 2019 11:00 ET (15:00 GMT)

Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191209 03:47:28